Recombinant Human ALCAM Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human ALCAM Fc Chimera Protein, CF Summary

• Additional Information: A New and Improved rh ALCAM is Available! ~2 fold better activity; HEK293 expressed; no His tag!
• Details of Functionality: Measured by its ability to block adhesion of HuT 78 human cutaneous T cell lymphoma cells to immobilized Recombinant Human CD6 Fc Chimera (Catalog # 627-CD). The ED₅₀ for this effect is 0.3-1.5 μg/mL.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Mouse myeloma cell line, NS0-derived human ALCAM/CD166 protein
  

  Human ALCAM (Trp28-Ala526) Accession # AAB59499	DIEGRMD	Human IgG1 (Pro100-Lys330)	6-His tag
  N-terminus			C-terminus

• Accession #: AAB59499
• N-terminal Sequence: Trp28
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: ALCAM
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 83.5 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 99-115 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ALCAM Fc Chimera Protein, CF

• activated leucocyte cell adhesion molecule
• activated leukocyte cell adhesion moleculeFLJ38514
• ALCAM
• CD166 antigen
• CD166
• MEMDMGC71733

Background

ALCAM (activated leukocyte cell adhesion molecule), designated CD166 and also called MEMD and SC‑1/DM‑GRASP/BEN in the chicken, is a 100‑110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). ALCAM is expressed on thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte‑derived dendritic cells (1, 2). Human ALCAM cDNA encodes 583 amino acid (aa), including signal peptide (27 aa), extracellular domain (ECD, 500 aa) with two V‑type and three C2‑type Ig‑like domains, transmembrane (22 aa) and cytoplasmic (34 aa) domains (1). Human ALCAM ECD shares 93%, 95% and 96% aa sequence identity with mouse/rat, bovine and porcine/equine ALCAM, respectively. A 570 aa isoform lacks aa 503‑515, while a 555 aa form lacks most of the cytoplasmic domain. A secreted isoform in endothelial cells that is truncated at aa 133 (sALCAM) antagonizes full‑length ALCAM (3, 4). ALCAM mediates low‑affinity adhesion with itself or the cysteine‑rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1‑11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4⁺CD8⁺ T cells (6). Adhesion of ALCAM‑expressing antigen presenting cells and CD6‑expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (2, 7, 8). High ALCAM expression at the blood‑brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on melanoma cell lines appears to be pro‑metastatic, but anti‑metastatic activity has been reported in breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM‑L1, both in the developing retina and invasive melanoma (3, 12).

1. Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
2. Zimmerman, A.W. et al. (2006) Blood 107:3212.
3. van Kilsdonk, J.W.J. et al. (2008) Cancer Res. 68:3671.
4. Ikeda, K. and T. Quertermous (2004) J. Biol. Chem. 279:55315.
5. van Kempen, L.C. et al. (2001) J. Biol. Chem. 276:25783.
6. Castro, M.A.A. et al. (2007) J. Immunol. 178:4351.
7. Nair, P. et al. (2010) Clin. Exp. Immunol. 162:116.
8. Masedunskas, A. et al. (2006) FEBS Lett. 580:2637.
9. Cayrol, R. et al. (2008) Nat. Immunol. 9:137.
10. Degen, W.G. et al. (1998) Am. J. Pathol. 152:805.
11. King, J.A. et al. (2010) Mol. Cancer 9:266.
12. Buhusi, M. et al. (2009) J. Neurosci. 29:15630.

Publications for ALCAM/CD166 (656-AL)(7)

Publications using 656-AL

• C Cegarra, B Cameron, C Chaves, T Dabdoubi, TM Do, B Genêt, V Roudières, Y Shi, P Tchepikoff, D Lesuisse An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family PLoS ONE, 2022;17(9):e0274667. 2022 [PMID: 36108060] (ELISA Capture, Human)
• U Bughani, A Saha, A Kuriakose, R Nair, RB Sadashivar, R Venkataram, S Patel, AT Deshchougu, SK S, E Montero, HV Pai, DV Palanivelu, R Melarkode, P Nair T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab PLoS ONE, 2017;12(7):e0180088. 2017 [PMID: 28672038] (Bioassay, Human)
• Carbotti G, Orengo A, Mezzanzanica D, Bagnoli M, Brizzolara A, Emionite L, Puppo A, Centurioni M, Bruzzone M, Marroni P, Rossello A, Canevari S, Ferrini S, Fabbi M Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors. Int J Cancer, 2013;132(11):2597-605. 2013 [PMID: 23169448] (Bioassay, Human)
• Ihnen M, Kress K, Kersten JF, Kilic E, Choschzick M, Zander H, Muller V, Mahner S, Janicke F, Woelber L, Milde-Langosch K Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients. BMC Cancer, 2012;12(0):140. 2012 [PMID: 22475274] (ELISA (Standard), N/A)
• Kulasingam V, Zheng Y, Soosaipillai A, Leon AE, Gion M, Diamandis EP Activated leukocyte cell adhesion molecule: a novel biomarker for breast cancer. Int. J. Cancer, 2009;125(1):9-14. 2009 [PMID: 19322904] (ELISA (Standard), N/A)
• Ibáñez A, Sarrias MR, Farnos M, Gimferrer I, Serra-Pages C, Vives J, Lozano F Mitogen-activated protein kinase pathway activation by the CD6 lymphocyte surface receptor. J. Immunol., 2006;177(2):1152-9. 2006 [PMID: 16818773] (Bioassay, Human)
• Zimmerman AW, Joosten B, Torensma R, Parnes JR, van Leeuwen FN, Figdor CG Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells. Blood, 2006;107(8):3212-20. 2006 [PMID: 16352806] (Bioassay, Human)

Bioinformatics

• Gene Symbol: ALCAM
• Uniprot:
  • AAB59499()